CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published ahead of print on January 25, 2006
Clin J Am Soc Nephrol 1: 433-440, 2006
© 2006 American Society of Nephrology
doi: 10.2215/CJN.01751105
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.01751105v1
1/3/433    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akalin, E.
Right arrow Articles by Pascual, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akalin, E.
Right arrow Articles by Pascual, M.

Moving Points in Nephrology

Sensitization after Kidney Transplantation

Enver Akalin*, and Manuel Pascual{dagger}

* Renal Division and Recanati/Miller Transplantation Institute, Mount Sinai Medical School, New York, New York; and {dagger} Transplantation Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Address correspondence to: Dr. Enver Akalin, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1104, New York, NY 10029. Phone: 212-659-8003; Fax: 212-348-2474 E-mail: enver.akalin{at}msnyuhealth.org

Kidney transplant recipients may develop de novo anti-HLA and non-HLA antibodies after transplantation. Although these antibodies may be donor-specific or non–donor-specific, their presence may increase the risk for acute and chronic rejection, thereby decreasing allograft survival. The introduction of more sensitive and specific methods to detect anti-HLA antibodies, such as Flow Specific Beads and FlowPRA, both before and after transplantation, will help to define immunologically high-risk kidney transplant recipients. Thus, posttransplantation monitoring of anti-HLA antibody production will allow the identification of kidney transplant recipients who might be at increased risk for late allograft failure. Moreover, knowledge of alloantibody status after transplantation may help to guide the appropriate use of immunomodulatory agents to downregulate anti-HLA antibody production.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Li, P. Wadia, R. Chen, N. Kambham, M. Naesens, T. K. Sigdel, D. B. Miklos, M. M. Sarwal, and A. J. Butte
Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures
PNAS, March 17, 2009; 106(11): 4148 - 4153.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
E. Akalin, R. Dinavahi, R. Friedlander, S. Ames, G. de Boccardo, V. Sehgal, B. Schroppel, M. Bhaskaran, S. Lerner, M. Fotino, et al.
Addition of Plasmapheresis Decreases the Incidence of Acute Antibody-Mediated Rejection in Sensitized Patients with Strong Donor-Specific Antibodies
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1160 - 1167.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Society of Nephrology.